SCHEMBL13814818

SCHEMBL13814818

O=C(O)CCCc1ccc(NC(=O)c2cccc(Br)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
LMNA P02545 1/20 0.57
KDM4E B2RXH2 1/20 0.57
MAPT P10636 1/20 0.57
RAB9A P51151 4/20 0.57
GAA P10253 1/20 0.57
HTT P42858 1/20 0.57
ITGB3 P05106 1/20 0.56
ITGB1 P05556 1/20 0.56
ITGAV P06756 1/20 0.56
ITGA2B P08514 1/20 0.56
ITGB5 P18084 1/20 0.56
NPC1 O15118 3/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
TP53 P04637 2/20 0.55
FFAR1 O14842 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13593298 0.89 MEN1 (0.57) SMN1; SMN2LMNAKDM4EMAPTRAB9A
SCHEMBL10102714 0.85 NR1H4 (0.72) NR1H4SMN1; SMN2KDM4ERAB9AITGB3
SCHEMBL13618528 0.85 MEN1 (0.72) NR1H4LMNAKDM4EMAPTRAB9A
SCHEMBL13593586 0.85 NR1H4 (0.58) NR1H4SMN1; SMN2KDM4EITGB3ITGB1
SCHEMBL2060736 0.85 NR1H4 (0.58) NR1H4SMN1; SMN2KDM4EITGB3ITGB1
SCHEMBL14595003 0.85 ITGB3 (0.59) NR1H4SMN1; SMN2KDM4EITGB3ITGB1
SCHEMBL13814817 0.84 NR1H4 (0.71) NR1H4KDM4EMAPTNPC1TRPV1
SCHEMBL14088989 0.82 NR1H4 (0.81) NR1H4SMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL1468045 0.81 NR1H4 (0.58) NR1H4SMN1; SMN2KDM4EMAPTRAB9A
SCHEMBL31661752 0.81 NPC1 (0.66) NR1H4SMN1; SMN2KDM4ERAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION LE ROUX DANIELLE MARIE (US) 2026-03-19 US disclosed
US-7553872-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2009-06-30 US disclosed
US-7553872-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2009-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION VIP, GIPR, SLC10A2 NR1H4 264/4885SMN1; SMN2 1507/4885LMNA 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.